PEcoma Market: Current Analysis and Forecast (2023-2030)

Perivascular epithelioid cell tumors, also known as PEComa, represent a rare type of mesenchymal neoplasm that originates from perivascular epithelioid cells. These tumors can occur in various organs throughout the body, such as the uterus, kidney, liver, and gastrointestinal tract. PEComa is considered a challenging disease due to its rarity and the limited understanding surrounding its pathogenesis. Further, continuous rise in the incidences of Pecoma is also driving the market. For instance, as per the National Organization for Rare Disorders, Malignant PEComas are estimated to be diagnosed in 0.12 to 0.24 per one million people.

The PEcoma market was valued at USD 45.5 million in 2022 and is expected to grow at a CAGR of around 5% from 2023-2030.

Based on the type, the market is segmented into diagnosis and Treatment. The treatment category dominated the market in 2022. Regarding therapeutic options, surgery is the primary treatment modality for PEComa, particularly for localized disease. Complete surgical resection is the aim, as it significantly improves patients' outcomes. However, the effectiveness of surgery in advanced or metastatic cases is limited. Thus, there is a growing demand for targeted therapies that can effectively treat unresectable or metastatic PEComa.

On the basis of end-users, the market is categorized into Hospitals, diagnostic centers, and Others. Among these, the hospital's category held a significant market share in 2022. This is mainly due to the high volume of PEcome surgeries and treatments performed in hospitals, as well as the availability of advanced medical equipment and expertise in this setting.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America held dominating share of PEcoma market in 2022. The presence of well-established healthcare infrastructure, along with the increasing healthcare expenditure in the countries is the major attributing factor for the market growth in North America.

Some of the major players operating in the market include: Sarcoma Oncology Research Center LLC, Aadi Bioscience Inc, Novartis Pharmaceuticals, CENTOGENE GmbH Rostock, Antia Therapeutics AG, InCor Heart Institute, Children's Hospital Medical Center, Johnson & Johnson, Pfizer, and Mylan N.V.